Literature DB >> 8800106

Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience.

E J Lesnefsky1, C F Lundergan, J M Hodgson, R Nair, J S Reiner, S W Greenhouse, R M Califf, A M Ross.   

Abstract

OBJECTIVE: This study sought to determine whether the recovery of regional and global left ventricular function is reduced in elderly patients despite successful thrombolytic therapy for acute myocardial infarction. Comparisons were made between elderly (> or = 75 years old, n = 47) and adult (< 75 years old, n = 434) patients enrolled in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) angiographic trial who underwent catheterization at 90 min and 5 to 7 days after thrombolysis and who had an open infarct-related artery with Thrombolysis in Myocardial Infarction (TIMI) grade 2 to 3 flow at both times.
BACKGROUND: The morbidity and mortality of acute myocardial infarction is increased in elderly patients, presumably because of multiple adverse coexistent baseline variables. However, functional recovery after thrombolysis has not been characterized in the elderly.
METHODS: Ejection fraction, end-systolic volume index, infarct and noninfarct zone contractile function (SD/chord) and infarct extent (number of chords) were determined.
RESULTS: At 90 min, elderly patients with an open infarct-related artery had decreased infarct zone contractile function (-2.8 +/- 0.2 vs. -2.3 +/- 0.1 SD/chord in adults, p < or = 0.05) and a greater extent of injury (26.0 +/- 2.6 vs. 20.7 +/- 0.8 chords in adults, p < or = 0.05). At 5- to 7-day follow-up ventriculography, ejection fraction was reduced, and end-systolic volume index was significantly increased in elderly patients compared with adults. The severity of regional wall motion dysfunction in the infarct zone was also greater in the elderly than in adults at 5- to 7-day follow-up (-2.6 +/- 0.2 vs. -1.9 +/- 0.1 SD/chord, respectively, p < or = 0.005). Non-infarct zone contractile function at 90-min ventriculography was similar in both groups. Despite a patent infarct-related artery at 90-min, the 30-day mortality rate in the elderly remained elevated (17.8%) compared with that of adults (4%) (p < or = 0.0001). Elderly patients were predominantly female and had a higher prevalence of hypertension, multivessel coronary disease, previous infarction, anterior infarctions and later time to treatment (between 3 and 6 h) than adults. However, age > or = 75 years remained an independent determinant by multivariable regression analysis of 1-week postinfarction end-systolic volume index, regional left ventricular dysfunction (p = 0.02 and p < or = 0.008, respectively) and 30-day mortality (p < or = 0.0001).
CONCLUSIONS: Elderly patients had increased damage in the infarct zone and had persistently increased mortality despite sustained infarct-related artery patency after successful thrombolysis. Although the causes are probably multifactorial, a more rapid progression of ischemic injury or a blunted postreperfusion recovery appears to contribute to the poorer outcomes in elderly patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800106     DOI: 10.1016/0735-1097(96)00148-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

Review 1.  Thrombolytic therapy in acute myocardial infarction.

Authors:  U Priglinger; K Huber
Journal:  Drugs Aging       Date:  2000-04       Impact factor: 3.923

2.  Acetyl-L-carnitine increases mitochondrial protein acetylation in the aged rat heart.

Authors:  Janos Kerner; Elizabeth Yohannes; Kwangwon Lee; Ashraf Virmani; Aleardo Koverech; Claudio Cavazza; Mark R Chance; Charles Hoppel
Journal:  Mech Ageing Dev       Date:  2015-02-07       Impact factor: 5.432

3.  Reperfusion therapy and mortality in octogenarian STEMI patients: results from the Belgian STEMI registry.

Authors:  Els H Vandecasteele; Marc De Buyzere; Sofie Gevaert; Antoine de Meester; Carl Convens; Philippe Dubois; Jean Boland; Peter Sinnaeve; Herbert De Raedt; Pascal Vranckx; Patrick Coussement; Patrick Evrard; Christophe Beauloye; Marc Renard; Marc J Claeys
Journal:  Clin Res Cardiol       Date:  2013-07-26       Impact factor: 5.460

4.  Cardiolipin as an oxidative target in cardiac mitochondria in the aged rat.

Authors:  Edward J Lesnefsky; Charles L Hoppel
Journal:  Biochim Biophys Acta       Date:  2008-06-02

Review 5.  Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3.

Authors:  Karol Szczepanek; Qun Chen; Andrew C Larner; Edward J Lesnefsky
Journal:  Mitochondrion       Date:  2011-09-10       Impact factor: 4.160

6.  Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats.

Authors:  Nelson Escobales; Rebeca E Nuñez; Sehwan Jang; Rebecca Parodi-Rullan; Sylvette Ayala-Peña; Joshua R Sacher; Erin M Skoda; Peter Wipf; Walter Frontera; Sabzali Javadov
Journal:  J Mol Cell Cardiol       Date:  2014-10-23       Impact factor: 5.000

7.  A new strategy to decrease cardiac injury in aged heart following ischaemia-reperfusion: enhancement of the interaction between AMPK and SIRT1.

Authors:  Qun Chen; Edward J Lesnefsky
Journal:  Cardiovasc Res       Date:  2018-05-01       Impact factor: 10.787

8.  Myocardial infarction in the elderly.

Authors:  Amelia Carro; Juan Carlos Kaski
Journal:  Aging Dis       Date:  2010-12-23       Impact factor: 6.745

9.  Cardioprotection and ageing.

Authors:  Yon Hee Shim
Journal:  Korean J Anesthesiol       Date:  2010-03-30

10.  Glutaredoxin regulates apoptosis in cardiomyocytes via NFkappaB targets Bcl-2 and Bcl-xL: implications for cardiac aging.

Authors:  Molly M Gallogly; Melissa D Shelton; Suparna Qanungo; Harish V Pai; David W Starke; Charles L Hoppel; Edward J Lesnefsky; John J Mieyal
Journal:  Antioxid Redox Signal       Date:  2010-06-15       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.